勃林格殷格翰survodutide的研究结果显示，64.5%的F2和F3期纤维化患者的肝纤维化得到突破性改善且MASH无恶化
勃林格殷格翰survodutide的研究结果显示，64.5%的F2和F3期纤维化患者的肝纤维化得到突破性改善且MASH无恶化
Region switcher
Use the region switcher to change your region and language preferences
返回
Change region and language
Search for a region
-
Global
-
Albania
-
Algeria
-
Argentina
-
Australia
-
Austria
-
Bahrain
-
Belarus
-
Belgium
-
Bosnia and Herzegovina
-
Botswana
-
Brazil
-
Bulgaria
-
Cambodia
-
Canada
-
Chile
-
Colombia
-
Croatia
-
Czech Republic
-
Denmark
-
Ecuador
-
Egypt
-
Estonia
-
Ethiopia
-
Finland
-
France
-
Germany
-
Ghana
-
Greece
-
Hong Kong (China)
-
Hungary
-
India
-
Indonesia
-
Iran
-
Ireland
-
Israel
-
Italy
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Latin America
-
Latvia
-
Lebanon
-
Libya
-
Lithuania
-
Mainland China
-
Malawi
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Middle East and North Africa
-
Moldova
-
Morocco
-
Namibia
-
Netherlands
-
New Zealand
-
Nigeria
-
Oman
-
Pakistan
-
Paraguay
-
Peru
-
Poland
-
Portugal
-
Qatar
-
Russia
-
Saudi Arabia
-
Serbia
-
Seychelles
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sub-Sahara Africa
-
Sudan
-
Sweden
-
Switzerland
-
Syria
-
Taiwan (China)
-
Tanzania
-
Thailand
-
Tunisia
-
Turkey
-
Uganda
-
Ukraine
-
United Arab Emirates
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Zimbabwe
Not what you are looking for?
Check out the global boehringer-ingelheim.com
请扫码关注我们
勃林格殷格翰官方
勃林格殷格翰HR
勃林格殷格翰动保